These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33307129)

  • 1. GlycA for long-term outcome in T2DM secondary prevention.
    Zierfuss B; Höbaus C; Herz CT; Pesau G; Mrak D; Koppensteiner R; Schernthaner GH
    Diabetes Res Clin Pract; 2021 Jan; 171():108583. PubMed ID: 33307129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study.
    Connelly MA; Gruppen EG; Wolak-Dinsmore J; Matyus SP; Riphagen IJ; Shalaurova I; Bakker SJ; Otvos JD; Dullaart RP
    Clin Chim Acta; 2016 Jan; 452():10-7. PubMed ID: 26549655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis.
    Fashanu OE; Oyenuga AO; Zhao D; Tibuakuu M; Mora S; Otvos JD; Stein JH; Michos ED
    Angiology; 2019 Sep; 70(8):737-746. PubMed ID: 31030528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study.
    Yubero-Serrano EM; Alcalá-Diaz JF; Gutierrez-Mariscal FM; Arenas-de Larriva AP; Peña-Orihuela PJ; Blanco-Rojo R; Martinez-Botas J; Torres-Peña JD; Perez-Martinez P; Ordovas JM; Delgado-Lista J; Gómez-Coronado D; Lopez-Miranda J
    Cardiovasc Diabetol; 2021 Mar; 20(1):72. PubMed ID: 33766036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker Glycoprotein Acetyls Is Associated With the Risk of a Wide Spectrum of Incident Diseases and Stratifies Mortality Risk in Angiography Patients.
    Kettunen J; Ritchie SC; Anufrieva O; Lyytikäinen LP; Hernesniemi J; Karhunen PJ; Kuukasjärvi P; Laurikka J; Kähönen M; Lehtimäki T; Havulinna AS; Salomaa V; Männistö S; Ala-Korpela M; Perola M; Inouye M; Würtz P
    Circ Genom Precis Med; 2018 Nov; 11(11):e002234. PubMed ID: 30571186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis.
    Joshi AA; Lerman JB; Aberra TM; Afshar M; Teague HL; Rodante JA; Krishnamoorthy P; Ng Q; Aridi TZ; Salahuddin T; Natarajan B; Lockshin BN; Ahlman MA; Chen MY; Rader DJ; Reilly MP; Remaley AT; Bluemke DA; Playford MP; Gelfand JM; Mehta NN
    Circ Res; 2016 Nov; 119(11):1242-1253. PubMed ID: 27654120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis.
    Ezeigwe A; Fashanu OE; Zhao D; Budoff MJ; Otvos JD; Thomas IC; Mora S; Tibuakuu M; Michos ED
    Atherosclerosis; 2019 Mar; 282():91-99. PubMed ID: 30716566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher circulating GlycA, a pro-inflammatory glycoprotein biomarker, relates to lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in diabetic or metabolic syndrome subjects.
    Gruppen EG; Connelly MA; Dullaart RP
    J Clin Lipidol; 2016; 10(3):512-8. PubMed ID: 27206938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GlycA, a novel inflammatory marker, is associated with subclinical coronary disease.
    Tibuakuu M; Fashanu OE; Zhao D; Otvos JD; Brown TT; Haberlen SA; Guallar E; Budoff MJ; Palella FJ; Martinson JJ; Akinkuolie AO; Mora S; Post WS; Michos ED
    AIDS; 2019 Mar; 33(3):547-557. PubMed ID: 30475263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis.
    Ormseth MJ; Chung CP; Oeser AM; Connelly MA; Sokka T; Raggi P; Solus JF; Otvos JD; Stein CM
    Arthritis Res Ther; 2015 May; 17(1):117. PubMed ID: 25956924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired HDL Metabolism Links GlycA, A Novel Inflammatory Marker, with Incident Cardiovascular Events.
    Riggs KA; Joshi PH; Khera A; Singh K; Akinmolayemi O; Ayers CR; Rohatgi A
    J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study.
    Muhlestein JB; May HT; Galenko O; Knowlton KU; Otvos JD; Connelly MA; Lappe DL; Anderson JL
    Am Heart J; 2018 Aug; 202():27-32. PubMed ID: 29803983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
    Otvos JD; Guyton JR; Connelly MA; Akapame S; Bittner V; Kopecky SL; Lacy M; Marcovina SM; Muhlestein JB; Boden WE
    J Clin Lipidol; 2018; 12(2):348-355.e2. PubMed ID: 29409728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study.
    Sigvant B; Hasvold P; Kragsterman B; Falkenberg M; Johansson S; Thuresson M; Nordanstig J
    J Vasc Surg; 2017 Aug; 66(2):507-514.e1. PubMed ID: 28433332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Smoking and Serum GlycA and High-Sensitivity C-Reactive Protein Levels: The Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
    Kianoush S; Bittencourt MS; Lotufo PA; Bensenor IM; Jones SR; DeFilippis AP; Toth PP; Otvos JD; Tibuakuu M; Hall ME; Harada PHN; Blaha MJ
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28838917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes.
    Esteghamati A; Aflatoonian M; Rad MV; Mazaheri T; Mousavizadeh M; Nakhjavani M; Noshad S
    Arch Cardiovasc Dis; 2015; 108(8-9):412-9. PubMed ID: 26184866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GlycA, a Pro-Inflammatory Glycoprotein Biomarker, and Incident Cardiovascular Disease: Relationship with C-Reactive Protein and Renal Function.
    Gruppen EG; Riphagen IJ; Connelly MA; Otvos JD; Bakker SJ; Dullaart RP
    PLoS One; 2015; 10(9):e0139057. PubMed ID: 26398105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single and combined effects of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events: A prospective cohort study.
    Saely CH; Schindewolf M; Zanolin D; Heinzle CF; Vonbank A; Silbernagel G; Leiherer A; Drexel H; Baumgartner I
    Atherosclerosis; 2018 Dec; 279():32-37. PubMed ID: 30399464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel protein glycan biomarker and LCAT activity in metabolic syndrome.
    Gruppen EG; Connelly MA; Otvos JD; Bakker SJ; Dullaart RP
    Eur J Clin Invest; 2015 Aug; 45(8):850-9. PubMed ID: 26081900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Predictive Value of GlycA and Other Biomarkers of Inflammation for Total Death, Incident Cardiovascular Events, Noncardiovascular and Noncancer Inflammatory-Related Events, and Total Cancer Events.
    Duprez DA; Otvos J; Sanchez OA; Mackey RH; Tracy R; Jacobs DR
    Clin Chem; 2016 Jul; 62(7):1020-31. PubMed ID: 27173011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.